SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Amarantus Biosciences (AMBS : OTC.BB)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Jerseyfish6/14/2013 5:36:31 AM
   of 9
 
Business Summary
Amarantus BioScience Holdings, Inc., a development-stage biotechnology company, focuses on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases in the United States. The company is developing the Mesencephalic-Astrocyte-derived Neurotrophic Factor, a therapeutic protein to treat Parkinson?s diseases, as well as for other apoptosis-related disorders, including ischemic heart disease, traumatic brain injury, and orphan diseases; LymPro, blood test to diagnose Alzheimer?s disease; NuroPro to diagnose neurodegenerative diseases; and BC-SeraPro to diagnose breast cancer. It also owns PhenoGuard cell lines for the screening and discovery of biologic drug candidates and biomarkers of the central nervous system. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in Sunnyvale, California.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext